EUVIMEDEUVIMED entdecken
Crossref

Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells

S Momsen Reincke, Niels von Wardenburg, Marie A Homeyer, Hans-Christian Kornau, Gregorio Spagni, Lucie Y Li, Jakob Kreye, Elisa Sánchez-Sendín, Sonja Blumenau, Dominik Stappert, Helena Radbruch, Anja E Hauser und 4 weitere

Cell · 2023-11 · 186 (23) · 5084-5097.e18

DOI: 10.1016/j.cell.2023.10.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2023-11. Verfasst von S Momsen Reincke und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; German Center for Neurodegenerative Diseas…. Hauptthemen laut MEDLINE: Autoantibodies, Encephalitis, T-Lymphocytes. Die Arbeit wurde bisher 148-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft, Einstein Stiftung Berlin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-NMDA receptor (NMDAR) autoantibodies cause NMDAR encephalitis, the most common autoimmune encephalitis, leading to psychosis, seizures, and autonomic dysfunction. Current treatments comprise broad immunosuppression or non-selective antibody removal. We developed NMDAR-specific chimeric autoantibody receptor (NMDAR-CAAR) T cells to selectively eliminate anti-NMDAR B cells and disease-causing autoantibodies. NMDAR-CAARs consist of an extracellular multi-subunit NMDAR autoantigen fused to intracellular 4-1BB/CD3ζ domains. NMDAR-CAAR T cells recognize a large panel of human patient-derived autoantibodies, release effector molecules, proliferate, and selectively kill antigen-specific target cell lines even in the presence of high autoantibody concentrations. In a passive transfer mouse model, NMDAR-CAAR T cells led to depletion of an anti-NMDAR B cell line and sustained reduction of autoantibody levels without notable off-target toxicity. Treatment of patients may reduce side effects, prevent relapses, and improve long-term prognosis. Our preclinical work paves the way for CAAR T cell phase I/II trials in NMDAR encephalitis and further autoantibody-mediated diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesEncephalitisT-LymphocytesAnimalsHumansMiceReceptors, N-Methyl-D-AspartateAutoimmune DiseasesDisease Models, Animal

Stichwörter der Autor:innen

CAAR T cellNMDA receptor encephalitisT cellsautoimmune encephalitisautoimmunitycell therapychimeric autoantibody receptor

Substanzen

AutoantibodiesReceptors, N-Methyl-D-Aspartate

Autor:innen und Institutionen

  • Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany; Berlin Institute of Health at Chari…
  • Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.
  • German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany; Neuroscience Research Center (NWFZ), Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany; Department of Neuroscience, Catholi…
  • German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Pediatric Neurology, Charité - Universitäts…
  • Department of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Förderung

  • Bundesministerium für Bildung und Forschung
  • Deutsche Forschungsgemeinschaft
  • Einstein Stiftung Berlin
  • Deutsches Zentrum für Neurodegenerative Erkrankungen
  • Charité – Universitätsmedizin Berlin
  • Helmholtz Association

Zitieren

APA

Reincke, S. M., von Wardenburg, N., Homeyer, M. A., Kornau, H. C., Spagni, G., Li, L. Y., Kreye, J., Sánchez-Sendín, E., Blumenau, S., Stappert, D., Radbruch, H., Hauser, A. E., Künkele, A., Edes, I., Schmitz, D., & Prüss, H. (2023). Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell, 186(23), 5084-5097.e18. https://doi.org/10.1016/j.cell.2023.10.001

Vancouver

Reincke SM, von Wardenburg N, Homeyer MA, Kornau HC, Spagni G, Li LY, et al. Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell. 2023;186(23):5084-5097.e18. doi:10.1016/j.cell.2023.10.001

BibTeX
@article{Reincke2023,
  author = {Reincke, S Momsen and von Wardenburg, Niels and Homeyer, Marie A and Kornau, Hans-Christian and Spagni, Gregorio and Li, Lucie Y and Kreye, Jakob and Sánchez-Sendín, Elisa and Blumenau, Sonja and Stappert, Dominik and Radbruch, Helena and Hauser, Anja E and Künkele, Annette and Edes, Inan and Schmitz, Dietmar and Prüss, Harald},
  title = {Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells},
  journal = {Cell},
  year = {2023},
  volume = {186},
  number = {23},
  pages = {5084--5097.e18},
  doi = {10.1016/j.cell.2023.10.001}
}
Kostenlos starten →